13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
32 檔
11.0%
As reported in its official Q1 2025 Form 13F filing, Great Point Partners LLC's tracked investment portfolio stood at $529.1M with 32 total positions.
Great Point Partners LLC executed strategic sector rebalancing during Q1 2025, establishing 32 new positions while fully exiting 30 holdings and trimming 0 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CYTK | Cytokinetics Inc | Stock-Healthcare | 7.88% | — | +2.78% | |
| 2 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 6.20% | -3.12% | EXIT | |
| 3 | EOLS | Evolus Inc | Stock-Other | 6.02% | — | +5.50% | |
| 4 | ABVX | Abivax Sa-adr | Stock-Other | 5.42% | +15.22% | NEW | |
| 5 | VRDN | Viridian Therapeutics Inc | Stock-Other | 5.35% | — | — | |
| 6 | ✓ | Merus N V | Stock-Other | 5.29% | — | +50.01% | |
| 7 | AKBA | Akebia Therapeutics Inc | Stock-Other | 5.06% | — | — | |
| 8 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.36% | — | — | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 4.13% | — | — | |
| 10 | DVAX | Dynavax Technologies CORP | Stock-Other | 4.09% | — | -30.71% | |
| 11 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 4.00% | — | -50.50% | |
| 12 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 3.40% | -3.21% | — | |
| 13 | IMVT | Immunovant Inc | Stock-Other | 3.39% | -3.11% | EXIT | |
| 14 | ✓ | Stock-Other | 3.34% | — | — | ||
| 15 | NGNE | Neurogene Inc | Stock-Other | 2.92% | -0.23% | +6.37% | |
| 16 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.64% | — | — | |
| 17 | SMMT | Summit Therapeutics Inc | Stock-Other | 2.55% | — | — | |
| 18 | LEGN | Legend Biotech Corp-adr | Stock-Other | 2.48% | — | — | |
| 19 | PCVX | Vaxcyte Inc | Stock-Other | 2.31% | — | — | |
| 20 | AUTL | Autolus Therapeutics PLC | Stock-Other | 2.24% | — | -9.32% | |
| 21 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 2.24% | — | -25.23% | |
| 22 | ✓ | Zura Bio LTD | Stock-Other | 2.17% | -1.07% | — | |
| 23 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.82% | — | — | |
| 24 | ACLXGBX | Arcellx Inc | Stock-Other | 1.56% | — | — | |
| 25 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 1.52% | — | +10.87% | |
| 26 | CNTX | Context Therapeutics Inc | Stock-Other | 1.52% | -1.35% | EXIT | |
| 27 | RZLT | Rezolute Inc | Stock-Other | 1.28% | +0.27% | +33.95% | |
| 28 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.14% | — | — | |
| 29 | VYGR | Voyager Therapeutics Inc | Stock-Other | 1.12% | — | -24.25% | |
| 30 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 0.97% | — | — | |
| 31 | UPB | Upstream Bio Inc | Stock-Other | 0.97% | — | — | |
| 32 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.61% | — | -19.43% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MGNX | Macrogenics Inc | — | EXIT | Sold out |
| 2 | RCKT | Rocket Pharmaceuticals Inc | — | EXIT | Sold out |
| 3 | ARNAEUR | Arena Pharmaceuticals Inc | — | EXIT | Sold out |
| 4 | UTHR | United Therapeutics CORP | — | EXIT | Sold out |
| 5 | PODD | Insulet CORP | — | EXIT | Sold out |
| 6 | EXEL | Exelixis Inc | — | EXIT | Sold out |
| 7 | COLL | Collegium Pharmaceutical Inc | — | EXIT | Sold out |
| 8 | KDMN | Kadmon Holdings Inc | — | EXIT | Sold out |
| 9 | NTLA | Intellia Therapeutics Inc | — | EXIT | Sold out |
| 10 | MRTXEUR | Mirati Therapeutics Inc | — | EXIT | Sold out |
| 11 | TVTX | Travere Therapeutics Inc | — | EXIT | Sold out |
| 12 | AM6 | Amicus Therapeutics Inc | — | EXIT | Sold out |
| 13 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 14 | SG7 | Sage Therapeutics Inc | — | EXIT | Sold out |
| 15 | DYN | Dyne Therapeutics Inc | — | EXIT | Sold out |
| 16 | RPTX | Repare Therapeutics Inc | — | EXIT | Sold out |
| 17 | FGENEUR | Fibrogen Inc | — | EXIT | Sold out |
| 18 | OCUL | Ocular Therapeutix Inc | — | EXIT | Sold out |
| 19 | XENTEUR | Intersect Ent Inc | — | EXIT | Sold out |
| 20 | PBYI | Puma Biotechnology Inc | — | EXIT | Sold out |
| 21 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 22 | EOLS | Evolus Inc | — | NEW | New buy |
| 23 | BIIB | Biogen Inc | — | EXIT | Sold out |
| 24 | ✓ | Magenta Therapeutics Inc | — | EXIT | Sold out |
| 25 | KURA | Kura Oncology Inc | — | EXIT | Sold out |
| 26 | ANAB | Anaptysbio Inc | — | EXIT | Sold out |
| 27 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 28 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 29 | ✓ | Merus N V | — | NEW | New buy |
| 30 | AKBA | Akebia Therapeutics Inc | — | NEW | New buy |
| 31 | OLMA | Olema Pharmaceuticals Inc | — | EXIT | Sold out |
| 32 | 1T7 | Tricida Inc | — | EXIT | Sold out |
| 33 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 34 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 35 | DVAX | Dynavax Technologies CORP | — | NEW | New buy |
| 36 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 37 | IFRX | InflaRx N.V. | — | EXIT | Sold out |
| 38 | RIGLUSD | Rigel Pharmaceuticals Inc | — | EXIT | Sold out |
| 39 | AMLX | Amylyx Pharmaceuticals Inc | — | NEW | New buy |
| 40 | IMVT | Immunovant Inc | — | NEW | New buy |
| 41 | CTMX | Cytomx Therapeutics Inc | — | EXIT | Sold out |
| 42 | ✓ | — | NEW | New buy | |
| 43 | AGLEUSD | Aeglea Biotherapeutics Inc | — | EXIT | Sold out |
| 44 | NGNE | Neurogene Inc | — | NEW | New buy |
| 45 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 46 | SMMT | Summit Therapeutics Inc | — | NEW | New buy |
| 47 | LEGN | Legend Biotech Corp-adr | — | NEW | New buy |
| 48 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 49 | AUTL | Autolus Therapeutics PLC | — | NEW | New buy |
| 50 | ✓ | Helix Acquisition CORP Ii | — | NEW | New buy |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 32 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CYTK, 4XC1, EOLS) accounted for 11.0% of total reported equity market value during Q1 2025.
Top New Position Initiated
CYTK
市值: $14.9M
Top Position Liquidated / Trimmed
MGNX
前期市值: $37.0M
During Q1 2025, Great Point Partners LLC's top holdings by market value included CYTK (7.9%)、4XC1 (6.2%)、EOLS (6.0%). The largest single position, CYTK, represented 7.9% of total portfolio value.
In Q1 2025, Great Point Partners LLC made 62 total portfolio adjustments, initiating 32 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 30 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.